Advertisement
Screener

Cartesian Therapeutics, Inc. (RNAC) Accumulated Other Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

Cartesian Therapeutics, Inc. Accumulated Other Comprehensive Income

Cartesian Therapeutics, Inc. (RNAC) had Accumulated Other Comprehensive Income of -$4.61 million as of 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06

  • 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$4.61M.
  • 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$4.58M.
  • 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$4.58M.
  • 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$4.59M.
Period endAccumulated Other Comprehensive Income (Loss), Net of Tax
2026-06-30-$4.61M
10-Q · filed 2026-08-06
2026-03-31-$4.58M
10-Q · filed 2026-04-30
2025-12-31-$4.58M
10-Q · filed 2026-08-06
2025-09-30-$4.59M
10-Q · filed 2025-11-06
2025-06-30-$4.58M
10-Q · filed 2025-08-07
2025-03-31-$4.59M
10-Q · filed 2025-05-08
2024-12-31-$4.62M
10-K · filed 2026-03-09
2024-09-30-$4.61M
10-Q · filed 2024-11-07
2024-06-30-$4.59M
10-Q · filed 2024-08-08
2024-03-31-$4.61M
10-Q · filed 2024-05-08
2023-12-31-$4.60M
10-K · filed 2025-03-13
2023-09-30-$4.62M
10-Q · filed 2023-11-13
2023-06-30-$4.60M
10-Q · filed 2023-08-17
2023-03-31-$4.57M
10-Q · filed 2023-05-04
2022-12-31-$4.56M
10-K · filed 2024-03-07
2022-09-30-$4.53M
10-Q · filed 2022-11-03
2022-06-30-$4.48M
10-Q · filed 2022-08-08
2022-03-31-$4.60M
10-Q · filed 2022-05-05
2021-12-31-$4.57M
10-K · filed 2023-03-02
2021-09-30-$4.56M
10-Q · filed 2021-11-09
2021-06-30-$4.56M
10-Q · filed 2021-08-12
2021-03-31-$4.57M
10-Q · filed 2021-05-13
2020-12-31-$4.56M
10-K · filed 2022-03-10
2020-09-30-$4.58M
10-Q · filed 2020-11-05
2020-06-30-$4.55M
10-Q · filed 2020-08-06
2020-03-31-$4.58M
10-Q · filed 2020-05-07
2019-12-31-$4.52M
10-K · filed 2021-03-12
2019-09-30-$4.53M
10-Q · filed 2019-11-08
2019-06-30-$4.53M
10-Q · filed 2019-08-08
2019-03-31-$4.53M
10-Q · filed 2019-05-09
2018-12-31-$4.56M
10-K · filed 2020-03-12
2018-09-30-$4.52M
10-Q · filed 2018-11-08
2018-06-30-$4.48M
10-Q · filed 2018-08-08
2018-03-31-$4.40M
10-Q · filed 2018-05-09
2018-01-01-$4.42M
10-K · filed 2019-03-15
2017-12-31-$4.42M
10-K · filed 2019-03-15
2017-09-30-$4.41M
10-Q · filed 2017-11-07
2017-06-30-$4.41M
10-Q · filed 2017-08-11
2017-03-31-$4.38M
10-Q · filed 2017-05-11
2016-12-31-$4.52M
10-K · filed 2018-03-15
2016-09-30-$4.55M
10-Q · filed 2016-11-10
2016-06-30-$4.58M
10-Q · filed 2016-08-09
2015-12-31-$4.99M
10-K · filed 2017-03-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
MACROGENICS INC (MGNX)United States$0.242B-20.11
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23